Franklin Genomic Advancements ETF (HELX)
Cboe US • Currently down 0.52 (-1.19%) in today's trading session
1 member of Congress has disclosed 2 trades in Franklin Genomic Advancements ETF (HELX) via STOCK Act filings. The most recent disclosure was a sale by Kathy Castor on 6 April 2022. Aggregate disclosed activity totals roughly $16K in sales (midpoint estimates from bracketed disclosure amounts).
Franklin Genomic Advancements ETF is currently trading at $42.99, positioned at 96% of its 52-week range ($29.80 – $43.51).
Want to automatically copy Pelosi trades?
Mirror Nancy Pelosi's portfolio with just one click on eToro.
Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.
Past Performance is not an indication of future results.
Franklin Genomic Advancements ETF Price History and Technical Analysis
Congressional Trading Activity for HELX
| No data | |||||||
Select transactions to view their annotations on the chart
Similar Stocks
Based on congressional trading patterns
Frequently Asked Questions about HELX
- Which members of Congress have traded HELX?
- 1 member of Congress has disclosed 2 trade in Franklin Genomic Advancements ETF (HELX) under the STOCK Act: Kathy Castor.
- When was HELX most recently disclosed by Congress?
- The most recent HELX disclosure was a sale by Kathy Castor on 6 April 2022.
- What is the total disclosed congressional trading volume for HELX?
- Members of Congress have disclosed approximately $16K in HELX sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
- How can I track new congressional trades in HELX?
- This HELX page updates as soon as new STOCK Act disclosures are filed for Franklin Genomic Advancements ETF. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Track HELX in Congress
See when politicians buy or sell this stock